Abstract:
Preliminary data suggest that a tumor-infiltrating lymphocyte therapy called LN-145 may provide an option for patients with non-small cell lung cancer whose disease has progressed despite receiving other therapies, including PD-1 or PD-L1checkpoint inhibitors. Trial participants had an overall response rate of 21.4%, and the median duration of response had not been reached after 8.2 months of follow-up.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
